Form 4: Vera Therapeutics CEO Marshall Fordyce Executes Stock Options and Sells Shares
SEC Form 4 Filing
CEO Marshall Fordyce exercised stock options and sold shares of Vera Therapeutics (VERA) on January 8, 2025, according to a Form 4 filing with the SEC.
Summary
- On January 8, 2025, Marshall Fordyce, the President and CEO of Vera Therapeutics, exercised stock options to acquire 17,500 shares of Class A Common Stock at a price of $2.8968 per share.
- Fordyce then sold 17,500 shares of Class A Common Stock in multiple transactions at weighted-average prices of $41.5335 and $42.0334, and $42 per share.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 23, 2024.
- Following these transactions, Fordyce directly owns 143,603 shares of Class A Common Stock and indirectly owns 222,030 shares through a GRAT.
- He also directly owns options to purchase 609,051 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock transactions.
Industry Context
This filing is a routine disclosure of insider transactions and provides transparency to investors regarding the trading activities of company executives. It is common for executives to have pre-arranged trading plans like Rule 10b5-1 to manage their stock holdings.
Stakeholder Impact
- Shareholders are informed about the CEO's stock transactions, providing transparency into executive compensation and potential alignment of interests.
Key Dates
| Date | Description |
|---|---|
| December 16, 2021 | 1/4 of the shares subject to the option vested |
| April 23, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| January 8, 2025 | Date of stock option exercise and share sales |
| January 10, 2025 | Date of Form 4 filing |
| December 15, 2030 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.